FDA clears next-generation platform for AI-enabled ECG evaluations
AccurKardia, a New York-based medtech company, has received U.S. Food and Drug Administration (FDA) clearance for the latest version of its AccurECG Analysis Software, a fully automated platform that delivers rapid electrocardiogram (ECG) interpretations.
AccurECG 2.0 was designed to interpret a total of 13 different rhythm classifications, including atrial fibrillation, atrial flutter and ventricular tachycardia. According to AccurKardia, it was developed to be used by cardiac monitoring companies, device makers, hospitals and independent diagnostic testing facilities alike.
AccurECG 2.0 was designed to be device agnostic, meaning these artificial intelligence (AI) algorithms can be utilized by a wide range of stakeholders. The software can interpret test results originating from patches or any other traditional ECG devices.
“FDA clearance of AccurECG 2.0 is an important milestone for our company,” Juan C. Jiménez, co-founder and CEO of AccurKardia, said in a statement. “This clearance positions us to accelerate go-to-market efforts in the first half of 2026. With this clearance we can support significantly higher ECG volumes with consistent, near real-time interpretation, allowing our customers to expand monitoring programs without adding proportional clinical or operational burden.”
“With AccurECG 2.0, we are building on a clinically validated, FDA-cleared foundation to further support cardiac monitoring workflows that depend on fast, consistent, and high-quality interpretation,” added cardiologist Nav Razvi, MD, chief medical officer of AccurKardia. “As remote care continues to expand, software that improves efficiency while maintaining clinical standards can help extend access, especially in areas with limited specialist coverage.”
With the FDA clearance in place, AccurKardia has announced that it is immediately launching AccurECG 2.0 in the United States.
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.